Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 3.73
- Piotroski Score 3.00
- Grade Buy
- Symbol (BGNE)
- Company BeiGene, Ltd.
- Price $190.52
- Changes Percentage (-2.08%)
- Change -$4.04
- Day Low $189.01
- Day High $192.01
- Year High $248.16
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/24/2025
- Fiscal Year End N/A
- Average Stock Price Target $283.00
- High Stock Price Target $307.00
- Low Stock Price Target $196.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$7.53
- Trailing P/E Ratio -20.76
- Forward P/E Ratio -20.76
- P/E Growth -20.76
- Net Income $-881,708,000
Income Statement
Quarterly
Annual
Latest News of BGNE
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Here's Why BeiGene, Ltd. (BGNE) Rallied in Q3
Baird Asset Management's Chautauqua Capital Management released the Q3 2024 investor letter for the "Baird Chautauqua International and Global Growth Fund," showcasing strong performance in global equ...
By Yahoo! Finance | 1 month ago -
Beyond the Balance Sheet: What SWOT Reveals About BeiGene Ltd (BGNE)
BeiGene faces challenges in its growth due to competition and regulatory factors. Despite financial gains, net losses persist. With a robust product pipeline and global presence, the company aims for ...
By Yahoo! Finance | 3 months ago -
When Will BeiGene, Ltd. (NASDAQ:BGNE) Become Profitable?
BeiGene, Ltd., a leading oncology company, is progressing towards profitability with a projected breakeven in 2025. Analysts anticipate a profit of US$222m in 2026, expecting a 60% annual growth rate....
By Yahoo! Finance | 4 months ago
